The World Health Organisation (WHO) has prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a critical tool for safely administering WHO-recommended treatments to prevent relapse of Plasmodium vivax (P. vivax) malaria.
In a statement on Wednesday, WHO emphasised that the decision reflected updated processes designed to enhance efficiency and accessibility of life-saving health solutions globally.
The global health body said the prequalification of the G6PD diagnostic test is a significant milestone in ensuring safe and effective P. vivax malaria treatment, reaffirming its commitment to equitable access to essential health solutions worldwide.
